Therefore, by sustaining MAPK‐ERK1/2 overactivation, a signaling pathway frequently overridden in malignant transformation, FGF2 reinforces the dependence on stress‐response pathways, increasing the toxicity of stress‐targeted therapeutic inhibitors in both murine and human cancer cells. The gene discussed is FGF2; the disease is cancer.